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To the Editor: Extragonadal, nongestational choriocarcinomas are very rare neoplasms that mostly arise spontaneously in midline structures, such as the retroperitoneum, mediastinum, and vicinity of the pineal body, but they also have been reported in other visceral organs, such as the stomach, esophagus, small bowel, prostate, and urinary bladder. [1] In the last seven decades, there have been only 29 cases of male primary pulmonary choriocarcinoma (PPC) reported in the literature. Extragonadal choriocarcinoma arising in the lung is thought to be unresponsive to treatment and is associated with a poor prognosis. We report a 71-year-old male patient with extragonadal, nongestational choriocarcinoma apparently arising in the lung and review the characteristics of previously reported cases to explore the diagnosis and treatment of primary choriocarcinoma of the lung.
A 71-year-old man with a smoking history of 400 packs/year presented with cough and hemoptysis. A computed tomography (CT) scan revealed a 1.6-cm tumor with homogeneous density and smooth borders in the right medial lobe of the lung without swelling of the regional lymph nodes [ Figure 1a -1c]. Both abdominal and brain CT scans showed abnormal findings. The results of routine laboratory examinations were all normal except for carcinoembryonic antigen (7.3 ng/ml) and D-dimer (0.79 mg/L) levels. Percutaneous lung puncture by CT localization was performed, which led to a pathological diagnosis of carcinoma without determinative findings to specify the histologic subtype of a frozen section [ Figure 1d ]. Therefore, right medial lobectomy followed by systemic lymph node dissection was performed. Pathological examination of permanent sections evidenced mononuclear cytotrophoblastic cells and syncytiotrophoblastic giant cells that were positive for immunostaining of beta-human chorionic gonadotrophin (β-HCG) [ Figure 1e -1i]. No lymph node metastasis was observed. After the operation, serum and urine β-HCG levels were measured for the first time. The serum β-HCG level was 407.23 U/L (normal, 0-5 U/L), and the β-HCG level in the urine test was suspiciously positive. Systemic and genital screenings were performed by magnetic resonance imaging, CT scan, and ultrasonography, and the results displayed no abnormal findings. Thus, the final pathological diagnosis was choriocarcinoma that met the diagnostic criteria for PPC. No lymph node metastasis was detected, and the pathological stage was pT1aN0M0. Gene detection was performed and revealed eight genetic mutations, including two targeted drug-related mutations (STK11 and SMARCA4). Unfortunately, the patient declined chemotherapy and targeted therapy for economic reasons. The choriocarcinoma recurred 3 months after surgery [ Figure 1j -1l], and the patient died soon thereafter. This case has obtained informed consent from the patient and his family.
Due to infrequency of PPC, diagnosis before surgery is difficult unless β-HCG levels are measured. The diagnostic criteria for PPC include the lack of a previous urological malignancy, solitary or predominant lung lesion without a primary gonadal site, elevated serum chemotherapy, and pathologic confirmation of the disease. [1] In our case, the patient presented as a 71-year-old man with cough and hemoptysis. The preoperative β-HCG level was absent, and tumor cells were poorly differentiated. The diagnosis of PPC was based on histological features combined with immunohistochemical detection. In addition, the serum β-HCG level was confirmed to be significantly elevated postoperatively.
Since the lung is a frequent site of metastatic choriocarcinoma, the primary tumor should be diagnosed carefully. In this case, there were no lymph node metastasis and no apparent evidence of a primary genital tumor, and no lesions were found in midline structures or in other visceral organs by CT scan or abdominal echography. Nevertheless, the possibility of a metastasis from occult lesions in other locations could not be ruled out completely because the request for an autopsy was denied.
Currently, there is no established postoperative management for PPC because of its rarity. Male PPC is extremely rare, and 30 cases, including the current case, have been reported so far [Supplementary Table 1] . Patients with clinical data in publications were aged from 4 months to 77 years. [1] [2] [3] The median age of the patients was 53.1 years. Most patients had symptoms such as pleuritic pain, hemoptysis, dyspnea, cough, or precocious puberty, whereas 1 case was asymptomatic, and the tumor was discovered by chest roentgenogram. The fact that 8 cases have been diagnosed at autopsy reflects the aggressive nature of this tumor. Only 1 patient was diagnosed by a urine pregnancy test and bronchoscopic biopsy. One patient was diagnosed by CT-guided biopsy before the operation. Diagnosis is usually delayed until the patient is in the middle-late stage of the disease. Distant metastases are observed in many cases [1] [2] [3] at the time of diagnosis, and overall prognosis is extremely poor. Treatment data were available for 22 patients: 8 patients were treated with surgery and chemotherapy; 1 was treated with surgery and radiotherapy; 3 were treated with surgery, chemotherapy, and radiotherapy; 4 were treated with chemotherapy alone; 3 were treated with surgery alone; and 3 patients did not receive treatment and died quickly. Only 5 patients survived for >1 year.
The treatment strategies performed on patients included complete resection, chemotherapy, radiotherapy, supportive care, or a combination of the above treatments in published cases. At present, there is no evidence-based treatment recommendation, which makes it difficult to plan further therapy.
Next-generation sequencing is becoming more widely used as a valuable method for somatic mutation analysis in cancer. Comprehensive tumor mutation profiles can help identify biomarkers that are prognostic or predictive, relevant in clinical trials, or can be used for future development of novel therapies. We performed targeted capture sequencing covering 1021 cancer-related genes because little is known about the mutation profiles of choriocarcinomas. H and E, ×40) . The cytotrophoblastic cells grow in clusters separated and capped by syncytiotrophoblastic giant cells, thereby forming the characteristic biphasic pattern surrounded by a hemorrhagic area (e) (H and E, ×200). Higher magnification emphasizes the peripheral palisading by bizarre syncytiotrophoblasts (f) (H and E, ×400). Positive immunohistochemical staining for CK8 (g), CK19 (h), and β-HCG (i) was observed in the tumor cells (×200). (j-l) Chest CT findings 3 months after surgery. CT: Computed tomography; β-HCG: Beta-human chorionic gonadotrophin. STK11 c.291-1G>C is a conical splice site mutation. This variant has been reported as a somatic mutation in patients with lung cancer and as a germline mutation in patients with Peutz-Jeghers syndrome. In silico functional analysis predicted it to be a pathogenic loss of function mutation. It has been demonstrated that STK11 tumor suppressor negatively regulates mammalian target of rapamycin (mTOR) signaling; thus, loss of function mutation of STK11 may result in the activation of mTOR signaling. [4] Our finding was consistent with recent array comparative genomic hybridization (CGH) analysis of gestational and nongestational choriocarcinomas. In that study, in silico functional interaction analysis revealed involvement of the PI3K-Akt-mTOR signaling pathway in the pathobiology of choriocarcinomas.
The TP53 p.D281E mutation replaces a highly conserved aspartic acid (Asp, D) with glutamic acid (Glu, E) at codon 281 of the TP53 protein. This variant has been reported in ovary, lung, central nervous system, and hematopoietic cancers. [5] Experimental studies have shown that this missense change disrupts the transcriptional transactivation function of the TP53 protein. This finding suggests that the aspartic acid residue may be critical for TP53 protein function and that missense substitutions at this position may be pathogenic and may contribute to the development of choriocarcinoma. This finding was supported by a reported Japanese patient with gastric choriocarcinoma; mutational analysis of the TP53 gene in this patient revealed a point mutation in exon 5 (p.H179R). The authors concluded that mutation of the TP53 gene contributed to the oncogenesis of choriocarcinoma.
The SMARCA4 p.E1542* variant was a nonsense mutation that resulted in loss of function of SMARCA4. Although this mutation has not been reported in choriocarcinoma, loss of function mutation sensitized ovarian cancer cells to targeted therapy of vorinostat, a histone deacetylase inhibitor used in the management of cutaneous T-cell lymphoma. Other missense mutations were neither functionally tested nor reported in choriocarcinoma. Thus, those mutations might play a role as a "passenger mutation" in choriocarcinoma.
In summary, our comprehensive genetic profiling of choriocarcinoma showed that multiple somatic mutations occur in PPC. Abnormal TP53 and mTOR signaling might play a central role in PPC.
Supplementary information is linked to the online version of the paper on the Chinese Medical Journal website.
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